the aid library

LIST OPTIONS

Filter

10696

Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy

Tirados, I.; Esterhuizen, J.; Kovacic, V.; Mangwiro, TNC.; Vale, GA et al. PLOS Neglected Tropical Diseases (2015) CC

Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a full scale field trial of a refined vector control tec... more

External Link

Accelerating towards human African trypanosomiasis elimination: Issues and opportunities

Ozioko ,KU.; Okoye, CI.; Obiezue, RN.; Idika, IK.; Awudu, RA.; Ezewudo, BI.; Ezea, CO. (2019) CC

Human African trypanosomiasis (HAT) has been an alarming global public health issue. The disease affects mainly poor and marginalized people in low-resource settings and is caused by two subspecies of haemoflagellate parasite, Trypanosoma brucei and transmitted by tsetse flies. Progress made in HAT ... more

Download (181)

View PDF (225)

Trends in maternal mortality 2000 to 2020: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division

World Health Organisation (WHO) (2023) C_WHO

Every day in 2020, approximately 800 women died from preventable causes related to pregnancy and childbirth - meaning that a woman dies around every two minutes. Sustainable Development Goal (SDG) target 3.1 is to reduce maternal mortality to less than 70 maternal deaths per 100 000 live births by ... more

Download (171)

View PDF (175)

HIV self-testing at workplaces: approaches to implementation and sustainable financing

World Health Organisation (WHO) (2023) C_WHO

Countries are making progress toward the global goal of 95% of people living with HIV knowing their status by 2025. However, considerable gaps remain in achieving these goals globally. Men in high HIV burden settings and men from key populations in all settings are consistently less likely to know t... more

External Link

Leptospirosis – Fact Sheet - zoonotic disease with epidemic potential

Pan American Health Organization PAHO; World Health Organization WHO (2017) C_WHO

Leptospirosis is a zoonotic disease with epidemic potential, especially after a heavy rainfall, caused by a bacterium called Leptospira. Leptospira interrogans is pathogenic to humans and animals, with more than 200 serologic variants or serovars. Humans usually acquire leptospirosis through dire... more

External Link

Global Morbidity and Mortality of Leptospirosis: A Systematic Review

Costa, F.; Hagan, J.; Calcagno, J. PLoS Neglected Tropical diseases (2015) CC

Leptospirosis, a spirochaetal zoonosis, occurs in diverse epidemiological settings and affects vulnerable populations, such as rural subsistence farmers and urban slum dwellers. Although leptospirosis is a life-threatening disease and recognized as an important cause of pulmonary haemorrhage syndrom... more

External Link

Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis: learners’ guide

World Health Organization WHO; Institutional research information sharing iris (2013) C_WHO

Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis: learners’ guide. World Health Organization.

External Link

Global programme to eliminate lymphatic filariasis: progress report, 2020 - Weekly Epidemiological Record, 2021, vol. 96, 41 [‎full issue]‎

World Health Organization WHO; Institutional research information sharing iris (2021) C_WHO

Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co... more

External Link

Programme mondial pour l’élimination de la filariose lymphatique: rapport de situation, 2020 - Weekly Epidemiological Record, 2021, vol. 96, 41 [‎full issue]‎

World Health Organization WHO; Institutional research information sharing iris (2021) C_WHO

La filariose lymphatique (FL) est une maladie évitable, incapacitante et défigurante, due à une infestation par des filaires parasites des espèces Wuchereria bancrofti, Brugia malayi et B. timori. On estime que 51,4 millions de personnes sont infectées dans le monde. Le lymphœdème et l’hydr... more

External Link

Design and validation of a trachomatous trichiasis-only survey: strategic and technical advisory group for neglected tropical diseases, working group on monitoring and evaluation

World Health Organization WHO (2017) CC

The Fifty-first World Health Assembly adopted resolution WHA51.11 in 1998, which targets the global elimination of trachoma as a public health problem by 2020 (1). The strategy recommended to achieve that goal is encapsulated by the acronym “SAFE”, which represents: Surgery for individuals wi... more

Download (179)

View PDF (203)

WHO research for hand hygiene in health care 2023–2030: summary

World Health Organisation (WHO) (2023) C_WHO

Hand hygiene is vital for safe health care delivery, yet practices at the point of care remain suboptimal worldwide. A comprehensive research agenda is therefore necessary to improve our understanding of factors influencing hand hygiene behaviour and to strengthen appropriate interventions. This age... more

Download (257)

View PDF (366)

Policies to protect children from the harmful impact of food marketing: WHO guideline

World Health Organisation (WHO) (2023) C_WHO

Children continue to be exposed to powerful food marketing, which predominantly promotes foods high in saturated fatty acids, trans-fatty acids, free sugars and/or sodium and uses a wide variety of marketing strategies that are likely to appeal to children. Food marketing has a harmful impact on chi... more

External Link

Official development assistance for health—how neglected are neglected tropical diseases? An analysis of health financing

Liese B; Schubert L. Science Direct (2009) CC

The increasing amounts of official development assistance (ODA) for health have been aimed primarily at fighting HIV/AIDS, malaria and tuberculosis. Neglected tropical diseases (NTD), one of the most serious public health burdens among the most deprived communities, have only recently drawn the atte... more

Download (117)

View PDF (108)

WHO tool for benchmarking ethics oversight of health-related research involving human participants: user guide

World Health Organization WHO (2023) C_WHO

Jointly developed by WHO’s Regulatory System Strengthening, Regulation and Safety Unit and the Health Ethics & Governance Unit, it is intended to assist countries in evaluating their capacity to provide appropriate ethical oversight of health-related research. In addition to assisting in capacity-... more

Tracking development assistance for health to fragile states: 2005-2011

Graves C. et al. Pubmed (2023) CC

Development assistance for health (DAH) has grown substantially, totaling more than $31.3 billion in 2013. However, the degree that countries with high concentrations of armed conflict, ethnic violence, inequality, debt, and corruption have received this health aid and how that assistance might be d... more

Responding to communicable and noncommunicable diseases: progress report 2020-2022

World Health Organization WHO (2023) C_WHO

Significant progress has been made in the eradication of three priority diseases in the African Region, as a result of extensive collaboration between the Regional Office, WHO country offices and countries. For example, in August 2020, the region was certified free of wild poliovirus. In the area of... more

Guidance for country validation of viral hepatitis elimination and path to elimination

World Health Organization WHO (2023) C_WHO

Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Empowering Frontline Primary Healthcare Workers in a Global Health Partnership Training of Trainers Intervention to Strengthen the Prevention and Control of Cardiovascular Disease in Mozambique

Harris. P.; Juga, E.; Bay, N. et al. Global Heart (2022) CC

Unpreparedness of health professionals to address non-communicable diseases (NCD) at peripheral health facilities is a critical health system challenge in Mozambique. To address this weakness and decentralize NCD care, training of the primary care workforce is needed. We describe our experience in t... more

External Link

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease

Abola, M. T. B.; Golledge, J.; Miyata, T. et al. Journal of Atherosclerosis and Thrombosis (2020) CC

Peripheral artery disease (PAD) is the most underdiagnosed, underestimated and undertreated of the atherosclerotic vascular diseases despite its poor prognosis. There may be racial or contextual differences in the Asia-Pacific region as to epidemiology, availability of diagnostic and therapeutic mod... more